Prostate Cancer Specialty Channel

Conference Coverage

First-Line Enzalutamide Plus Ra223 Significantly Improves Radiological PFS in Metastatic Castration-Resistant Prostate Cancer

09/14/2024

Janelle Bradley ;

Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.

Findings from the phase 3...

09/14/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...

According to long-term results...

05/14/2024

Oncology

News

Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy

04/03/2024

Stephanie Holland

According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...

According to results from the...

04/03/2024

Oncology

News

Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer

02/23/2024

Allison Casey

According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...

According to interim results...

02/23/2024

Oncology

Conference Coverage

Dose-Escalated Radiotherapy Plus Long-Term Androgen-Deprivation Therapy Deemed Safe, Effective for High-Risk Prostate Cancer

01/25/2024

Allison Casey ;

According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.

According to a phase 3 trial,...

01/25/2024

Oncology

Quiz

Improving Detection of Clinically Significant Prostate Cancer

01/15/2024

True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.

True or False: Adding the...

01/15/2024

Oncology

News

PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer

01/12/2024

Allison Casey ;

In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.

In a retrospective cohort study,...

01/12/2024

Oncology

News

Actinium-255-PSMA Radioligand Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer

01/12/2024

Allison Casey ;

According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.

According to a retrospective...

01/12/2024

Oncology

News

Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

01/05/2024

Allison Casey ;

A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.

A real world study found triplet...

01/05/2024

Oncology

News

Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer

12/12/2023

Allison Casey ;

According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.

According to sensitivity...

12/12/2023

Oncology

News

Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups

12/01/2023

Allison Casey ;

According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.

According to an exploratory...

12/01/2023

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results...

05/14/2024

Oncology

News

Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy

04/03/2024

Stephanie Holland

According to results from the...

04/03/2024

Oncology

News

Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer

02/23/2024

Allison Casey

According to interim results...

02/23/2024

Oncology

Conference Coverage

Dose-Escalated Radiotherapy Plus Long-Term Androgen-Deprivation Therapy Deemed Safe, Effective for High-Risk Prostate Cancer

01/25/2024

Allison Casey ;

According to a phase 3 trial,...

01/25/2024

Oncology

News

PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer

01/12/2024

Allison Casey ;

In a retrospective cohort study,...

01/12/2024

Oncology

News

Actinium-255-PSMA Radioligand Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer

01/12/2024

Allison Casey ;

According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.

According to a retrospective...

01/12/2024

Oncology

News

Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

01/05/2024

Allison Casey ;

A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.

A real world study found triplet...

01/05/2024

Oncology

News

Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer

12/12/2023

Allison Casey ;

According to sensitivity...

12/12/2023

Oncology

News

Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups

12/01/2023

Allison Casey ;

According to an exploratory...

12/01/2023

Oncology

News

255AC-J591 Shows Preliminary Efficacy, Safety Among Patients with Metastatic Castration-Resistant Prostate Cancer

11/30/2023

Allison Casey ;

According to a phase 1 trial, a single dose of 255AC-J591 was safe and showed preliminary efficacy among patients with metastatic castration-resistant prostate cancer.

According to a phase 1 trial, a...

11/30/2023

Oncology

Interactive Features

Quiz

Improving Detection of Clinically Significant Prostate Cancer

01/15/2024

True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.

True or False: Adding the...

01/15/2024

Oncology

Quiz

Adjuvant Radiotherapy Following Radical Prostatectomy

11/13/2023

Allison Casey ;

Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.

Test your knowledge on the...

11/13/2023

Oncology

Quiz

Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.

Test your knowledge with this...

11/10/2023

Oncology

Quiz

Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial

11/10/2023

Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.

Test your knowledge with this...

11/10/2023

Oncology

Quiz

True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.

11/02/2022

True or False: A study found...

11/02/2022

Oncology

Quiz

Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer

09/02/2022

In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...

In the ENZAMET trial evaluating...

09/02/2022

Oncology

Quiz

Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?

07/21/2022

Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?

Quiz: The commercially-available...

07/21/2022

Oncology

Test Your Knowledge

Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?

09/02/2021

True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.

True or false: For patients with...

09/02/2021

Oncology

Test Your Knowledge

Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?

07/29/2021

True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.

True or False: Since small...

07/29/2021

Oncology

Test Your Knowledge

Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?

07/29/2021

Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?

Which treatment approach...

07/29/2021

Oncology

Recent News

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results...

05/14/2024

Oncology

News

Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy

04/03/2024

Stephanie Holland

According to results from the...

04/03/2024

Oncology

News

Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer

02/23/2024

Allison Casey

According to interim results...

02/23/2024

Oncology

News

PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer

01/12/2024

Allison Casey ;

In a retrospective cohort study,...

01/12/2024

Oncology

News

Actinium-255-PSMA Radioligand Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer

01/12/2024

Allison Casey ;

According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.

According to a retrospective...

01/12/2024

Oncology

News

Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

01/05/2024

Allison Casey ;

A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.

A real world study found triplet...

01/05/2024

Oncology

News

Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer

12/12/2023

Allison Casey ;

According to sensitivity...

12/12/2023

Oncology

News

Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups

12/01/2023

Allison Casey ;

According to an exploratory...

12/01/2023

Oncology

News

255AC-J591 Shows Preliminary Efficacy, Safety Among Patients with Metastatic Castration-Resistant Prostate Cancer

11/30/2023

Allison Casey ;

According to a phase 1 trial, a single dose of 255AC-J591 was safe and showed preliminary efficacy among patients with metastatic castration-resistant prostate cancer.

According to a phase 1 trial, a...

11/30/2023

Oncology

News

Enzalutamide Approved for Non-Metastatic Castration Sensitive Prostate Cancer With Biochemical Recurrence

11/21/2023

Allison Casey ;

On November 17, 2023, the FDA approved enzalutamide for patients with non-metastatic castration sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

On November 17, 2023, the FDA...

11/21/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology